MedRx Co., Ltd Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2017 and for the Fiscal Year Ending December 31, 2017
May 11, 2017
Share
MedRx Co. Ltd. announced consolidated earnings results for the first quarter ended March 31, 2017. For the period, the consolidated company reported net sales of ¥18 million, operating loss of ¥212 million, ordinary loss of ¥222 million, net loss attributable to owners of the parent of the company of ¥192 million or net loss per basic share of ¥22.61 compared to net sales of ¥9 million, operating loss of ¥268 million, ordinary loss of ¥256 million, net loss attributable to owners of the parent of the company of ¥236 million or net loss per basic share of ¥33.33 for the same period last year.
For the six months ending June 30, 2017, the consolidated company expects net sales of ¥17 million, operating loss of ¥514 million, ordinary loss of ¥499 million, loss attributable to owners of the parent of the company of ¥459 million or net loss per share of ¥53.92.
For the fiscal year ending December 31, 2017, the consolidated company expects net sales of ¥186 million, operating loss of ¥186 million, ordinary loss of ¥1,244 million, loss attributable to owners of the parent of the company of ¥1,206 million or net loss per share of ¥141.70.
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
MedRx Co., Ltd Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2017 and for the Fiscal Year Ending December 31, 2017